Members of the genus including Jurona virus (JURV) have emerged as promising immunotherapeutic agents, characterized by their tumor selectivity, fast kinetics, low seroprevalence, and minimal toxicity in humans. Here, we demonstrate that the administration of JURV leads to tumor regression in both hepatocellular carcinoma (HCC) xenograft and syngeneic models. Furthermore, our findings indicate that combining JURV and anti-PD-1 therapy reduced tumor burden and improved survival rates over JURV or anti-PD-1 alone in an orthotopic HCC model.
View Article and Find Full Text PDFSince the early 20th century, the increase in non-communicable diseases such as diabetes, heart disease, stroke, and cancer compared to infectious diseases has led to chronic illnesses becoming a leading cause of global morbidity and mortality [...
View Article and Find Full Text PDF